Marsha Fanucci
Direktor/Vorstandsmitglied bei SYROS PHARMACEUTICALS, INC.
Vermögen: 101 786 $ am 31.05.2024
Profil
Marsha H.
Fanucci is currently the Director at Forma Therapeutics, Inc., the Director at The Schwartz Center for Compassionate Healthcare, and the Independent Director at Syros Pharmaceuticals, Inc. She previously served as the Chairman at Cyclerion Therapeutics, Inc., the Independent Director at Momenta Pharmaceuticals, Inc., the Independent Director at Ironwood Pharmaceuticals, Inc., the Independent Non-Executive Director at Forma Therapeutics Holdings, Inc., the Independent Director at Alnylam Pharmaceuticals, Inc., the Chief Financial Officer & Senior Vice President at Millennium Pharmaceuticals, Inc., the Vice President-Corporate Development & Strategy at Genzyme Corp., and the Vice President at Arthur D.
Little, Inc. Ms. Fanucci obtained her undergraduate degree from West Virginia University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
05.06.2024 | 16 000 ( 0,06% ) | 81 600 $ | 31.05.2024 | |
18.05.2023 | 136 ( 0,00% ) | 20 186 $ | 31.05.2024 |
Aktive Positionen von Marsha Fanucci
Unternehmen | Position | Beginn |
---|---|---|
SYROS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 19.10.2015 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Direktor/Vorstandsmitglied | 01.02.2014 |
The Schwartz Center for Compassionate Healthcare | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Marsha Fanucci
Unternehmen | Position | Ende |
---|---|---|
ALNYLAM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 29.09.2023 |
FORMA THERAPEUTICS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 14.10.2022 |
IRONWOOD PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.04.2019 |
MOMENTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 31.12.2016 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Finanzdirektor/CFO | 01.01.2009 |
Ausbildung von Marsha Fanucci
Northeastern University | Masters Business Admin |
West Virginia University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
SYROS PHARMACEUTICALS, INC. | Health Technology |
CYCLERION THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Arthur D. Little, Inc.
Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Commercial Services |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
The Schwartz Center for Compassionate Healthcare | |
Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |